Printer Friendly Version View printer-friendly version
« Back
Seattle Genetics Announces Relocation and Expansion of Corporate Headquarters
August 14, 2001 at 12:00 AM EDT

Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has relocated its corporate office and laboratory space to a new, significantly larger facility, located a short distance from their former site in Bothell’s Canyon Park area. The new headquarters building, which is 64,000 square feet, will allow for growth in all areas of the Company, including clinical, research and development. Seattle Genetics’ new address is 21823 30th Drive S.E., Bothell, WA, 98021. The Company’s main telephone number is (425) 527-4000.

About Seattle Genetics

Seattle Genetics discovers and develops monoclonal antibody, or mAb, -based therapeutics to treat cancer and related diseases. The Company has four technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy (ADEPT). Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company also out-licenses its mAb-based technologies to strategic partners developing targeted therapies. Seattle Genetics has agreements with many organizations including Genentech, Medarex, Aventis, Bristol-Myers Squibb, Eos Biotechnology, Arizona State University, the University of Miami, and CLB Research and Development. More information about Seattle Genetics can be found at www.seattlegenetics.com.

Certain of the statements made in this press release are forward-looking. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and additional costs related to managing and occupying a larger facility, adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early stage development and failure by Seattle Genetics to secure collaborators. More information about the risks and uncertainties faced by Seattle Genetics is contained in the Company’s filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Peggy Pinkston, Manager of Investor Relations
(425) 527-4160
ppinkston@seagen.com